The European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Study Group. Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage.

A. Algra

The European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Study Group. Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage.

Translated title of the contribution: The European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Study Group. Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage.

A. Algra

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	The European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Study Group. Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage.
Original language	Undefined/Unknown
Pages (from-to)	e45-e47
Number of pages	3
Journal	Stroke
Volume	34
Publication status	Published - 2003

Cite this

@article{b2912f820a104ee68959fd5a24872c67,

title = "The European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Study Group. Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage.",

author = "A. Algra",

year = "2003",

language = "Undefined/Unknown",

volume = "34",

pages = "e45--e47",

journal = "Stroke",

issn = "0039-2499",

publisher = "Wolters Kluwer Health",

}